Jenna Kerry, Author at EasyM - Multiple Myeloma Blood Test

Clinical Utility of Quantitative, Mass Spectrometry-Based EasyM for MRD Monitoring in Multiple Myeloma: Integration with Established MRD Detection Techniques in a Pan-Canadian Real-World Cohort Study

Jenna Kerry2026-02-24T16:25:21-05:00February 24th, 2026|Poster|

Introduction Minimal residual disease (MRD) negativity is a critical prognostic factor in multiple myeloma (MM), but conventional monitoring relies on invasive bone marrow (BM) testing and may miss disease due to spatial heterogeneity. EasyM is a mass spectrometry-based blood assay that tracks patient-specific M-protein peptides in peripheral blood, enabling frequent, non-invasive MRD [...]

0

Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions

Jenna Kerry2025-10-30T13:42:02-04:00October 30th, 2025|Publication|

Introduction Minimal residual disease (MRD) testing is the strongest prognostic metric for multiple myeloma (MM). By detecting even the smallest traces of disease, MRD offers a highly sensitive measure of treatment response and even goes beyond traditional remission criteria. Clinicians are now wondering how MRD can help shape clinical decision making in MM, especially [...]

0

Extramedullary Disease in Multiple Myeloma

Jenna Kerry2025-09-03T16:35:45-04:00September 3rd, 2025|Articles|

Introduction Multiple myeloma is cancer of plasma cells, a type of white blood cell found mainly in the bone marrow. Normal plasma cells are responsible for producing a mixture of many types of antibodies to protect your body against infections. In multiple myeloma, the abnormal plasma cells multiply uncontrollably and produce large [...]

0

Types of Multiple Myleoma

Jenna Kerry2025-09-03T16:07:39-04:00June 16th, 2025|Articles|

Introduction Multiple myeloma is a type of blood cancer that forms in plasma cells. Plasma cells, also known as plasmacytes, are a type of white blood cell located in the bone marrow that produce antibodies to fight infections. While the general diagnosis is known as "multiple myeloma", it actually comes in various [...]

0

Discontinuation of Maintenance Therapy in Multiple Myeloma Guided by Multimodal Measurable Residual Disease Negativity (MRD2STOP)

Jenna Kerry2025-06-11T15:55:48-04:00June 11th, 2025|Publication|

Introduction Once initial treatment of multiple myeloma is complete, maintenance therapy, often involving lenalidomide or proteasome inhibitors, is the standard of care. However, maintenance therapy can cause a number of negative side effects, such as toxicity, thereby reducing quality of life. Minimal residual disease (MRD) is a key predictor of outcomes in [...]

0

Minimal Residual Disease as a Primary Endpoint in Multiple Myeloma

Jenna Kerry2025-05-21T11:04:11-04:00May 21st, 2025|Publication|

Introduction In April 2024, the U.S. FDA’s Oncologic Drugs Advisory Committee (ODAC) unanimously (12–0) voted to accept minimal residual disease (MRD) negativity as a primary endpoint in multiple myeloma (MM) clinical trials seeking accelerated approval. This marks a regulatory shift, aiming to speed up the availability of new treatments. The decision stems [...]

0

Blood-based Measurable Residual Disease Measurement by Clonotypic Mass Spectrometry is Prognostic in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant

Jenna Kerry2025-05-15T10:08:14-04:00May 14th, 2025|Publication|

Introduction Minimal residual disease (MRD) is a critical prognostic indicator in multiple myeloma, typically assessed using invasive bone marrow-based assays. However, these methods have shown limited success when applied to blood. Next-generation flow (NGF) is mainly useful in patients with high levels of circulating disease, which is a phenomenon that has been [...]

0

Opportunities and Challenges for MRD Assessment in the Clinical Management of Multiple Myeloma

Jenna Kerry2025-05-12T11:32:03-04:00May 12th, 2025|Publication|

Introduction As detection technology and therapeutics have improved, minimal residual disease (MRD) has become a pivotal prognostic marker in multiple myeloma (MM), particularly for predicting progression free and overall survival. In 2024, the FDA consensus is that MRD negativity can be used as a clinical trial endpoint. This shift is driving innovation [...]

0

About Jenna Kerry

February 2026

Clinical Utility of Quantitative, Mass Spectrometry-Based EasyM for MRD Monitoring in Multiple Myeloma: Integration with Established MRD Detection Techniques in a Pan-Canadian Real-World Cohort Study

October 2025

Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions

September 2025

Extramedullary Disease in Multiple Myeloma

June 2025

Types of Multiple Myleoma

Discontinuation of Maintenance Therapy in Multiple Myeloma Guided by Multimodal Measurable Residual Disease Negativity (MRD2STOP)

May 2025

Minimal Residual Disease as a Primary Endpoint in Multiple Myeloma

Blood-based Measurable Residual Disease Measurement by Clonotypic Mass Spectrometry is Prognostic in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant

Opportunities and Challenges for MRD Assessment in the Clinical Management of Multiple Myeloma